Novartis’ experimental malaria treatment passed a Phase 3 trial, bringing it one step closer to becoming the newest tool in an aging arsenal of antimalarials.

The drug, called GanLum, was non-inferior to Novartis’ standard-of-care treatment …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844